Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of HAT1, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients With Moderate to Severe Atopic Dermatitis

NCT03059693 is registered in ClinicalTrials.gov with Haus Bioceuticals as lead sponsor.

NCT NCT03059693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03059693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of HAT1, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Haus Bioceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2016
Completion date
July 24, 2016
Enrollment
48 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic